Literature DB >> 2918308

Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note.

J D Fernstrom1.   

Abstract

The ingestion of aspartame, a phenylalanine-containing dipeptide, raises plasma phenylalanine levels. These increments are much greater in humans than rats, because the rat hydroxylates phenylalanine five times faster than man. Accordingly, dose comparisons of aspartame (or phenylalanine) between humans and rats have usually been corrected by a factor of five. Recently, a correction factor of sixty has been proposed (Wurtman and Maher, 1987); the rationale is based on a novel calculation of competitive phenylalanine transport into brain. An analysis of the logic behind this postulation reveals there to be no basis for accepting the higher dose conversion of 60 between rat and man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918308     DOI: 10.1007/BF01677429

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  9 in total

1.  Effects of oral aspartame on plasma phenylalanine in humans and experimental rodents. Short note.

Authors:  R J Wurtman; T J Maher
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

2.  Relationship of phenylalanine to seizure threshold during maturation.

Authors:  B B Gallagher
Journal:  J Neurochem       Date:  1970-03       Impact factor: 5.372

3.  Transport of metabolic substrates through the blood-brain barrier.

Authors:  W M Pardridge; W H Oldendorf
Journal:  J Neurochem       Date:  1977-01       Impact factor: 5.372

4.  The importance of transamination and decarboxylation in phenylalanine metabolism in vivo in the rat.

Authors:  C J Haley; A E Harper
Journal:  Arch Biochem Biophys       Date:  1978-08       Impact factor: 4.013

5.  Lack of effect of aspartame or of L-phenylalanine on photically induced myoclonus in the baboon, Papio papio.

Authors:  B S Meldrum; N Nanji; R G Cornell
Journal:  Epilepsy Res       Date:  1989 Jul-Aug       Impact factor: 3.045

6.  Studies on the phenylalanine hydroxylase system in vivo. An in vivo assay based on the liberation of deuterium or tritium into the body water from ring-labeled L-phenylalanine.

Authors:  S Milstien; S Kaufman
Journal:  J Biol Chem       Date:  1975-06-25       Impact factor: 5.157

7.  Psychoeducational findings among children treated for phenylketonuria.

Authors:  K Fishler; C G Azen; R Henderson; E G Friedman; R Koch
Journal:  Am J Ment Defic       Date:  1987-07

8.  Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus.

Authors:  H L Levy; S E Waisbren
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

9.  The conversion of phenylalanine to tyrosine in man. Direct measurement by continuous intravenous tracer infusions of L-[ring-2H5]phenylalanine and L-[1-13C] tyrosine in the postabsorptive state.

Authors:  J T Clarke; D M Bier
Journal:  Metabolism       Date:  1982-10       Impact factor: 8.694

  9 in total
  5 in total

1.  Aspartame and Soft Drink-Mediated Neurotoxicity in Rats: Implication of Oxidative Stress, Apoptotic Signaling Pathways, Electrolytes and Hormonal Levels.

Authors:  Mohamed A Lebda; Kadry M Sadek; Yasser S El-Sayed
Journal:  Metab Brain Dis       Date:  2017-06-28       Impact factor: 3.584

2.  Behavioral and electrophysiological brain effects of aspartame on well-nourished and malnourished rats.

Authors:  Paula Catirina Germano Magalhães; Ricardo Abadie-Guedes; Manoel Augusto Barbosa da Costa Mendonça; Aline Duarte de Souza; Rubem Carlos Araújo Guedes
Journal:  Metab Brain Dis       Date:  2018-12-13       Impact factor: 3.584

3.  Aspartame and seizures.

Authors:  P C Jobe; J W Dailey
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

Review 4.  Pharmacological effects of phenylalanine on seizure susceptibility: an overview.

Authors:  P Y Sze
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

5.  Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression.

Authors:  Kate S Collison; Angela Inglis; Sherin Shibin; Soad Saleh; Bernard Andres; Rosario Ubungen; Jennifer Thiam; Princess Mata; Futwan A Al-Mohanna
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.